Coherus Oncology (CHRS) Gross Margin (2019 - 2026)
Coherus Oncology (CHRS) posted Gross Margin of 69.02% for Q1 2026, up 1.09% sequentially from 68.27% in Q4 2025, and up 393.0% YoY from 14.0% in Q1 2025.
Coherus Oncology (CHRS) Gross Margin (2019 - 2026) Analysis & Trends
Coherus Oncology has reported Gross Margin for 8 years, with the latest figure at 69.02% in Q1 2026.
- Quarterly Gross Margin rose 393.0% year-over-year to 69.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 68.06% (down 56.0% YoY) and the FY2025 annual result came in at 67.24%, up 31.0% from the prior year.
- Gross Margin climbed to 69.02% in Q1 2026 per CHRS's latest filing, from 68.27% in the prior quarter.
- Over five years, Gross Margin peaked at 84.41% in Q1 2022 and troughed at 7.6% in Q4 2023.
- A 5-year average of 58.98% and a median of 65.09% in 2025 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin sank 6108 bps in 2023, then soared 5684 bps in 2024.
- Over 5 years, Gross Margin stood at 68.68% in 2022, then plunged by 89 bps to 7.6% in 2023, then jumped by 748 bps to 64.44% in 2024, then rose by 6 bps to 68.27% in 2025, then rose by 1 bps to 69.02% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 69.02%, 68.27%, and 67.84% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 70.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.35% |
| Mar 31, 2026 | 69.02% |
| Dec 31, 2025 | 68.27% |
| Sep 30, 2025 | 67.84% |
| Jun 30, 2025 | 66.89% |
| Mar 31, 2025 | 65.09% |
| Dec 31, 2024 | 64.44% |
| Sep 30, 2024 | 54.91% |
| Jun 30, 2024 | 82.43% |
| Mar 31, 2024 | 37.65% |
| Dec 31, 2023 | 7.60% |
| Sep 30, 2023 | 56.14% |
| Jun 30, 2023 | 57.68% |
| Mar 31, 2023 | 47.98% |
| Dec 31, 2022 | 68.68% |
| Sep 30, 2022 | 22.43% |
| Jun 30, 2022 | 81.25% |
| Mar 31, 2022 | 84.41% |
| Dec 31, 2021 | 83.50% |
| Sep 30, 2021 | 74.21% |